Skip to main content

Advertisement

Table 2 Studies included in comparisons. (a) 1 LVEF 44 trails, (b) LVEDD 8 trails, (c) LVESD 6 trails, (d) LVEDV 17 trails, (e) LVESV 15 trails, (f) LVMI 15 trails, (g) E/e′ 11 trails, (h) e′ 5 trails, (i) E/A 14 trails included

From: Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis

TreatmentNo. of trialsTotal no. of patients
a) LVEF 44 trails
 Control381635
 DPP-4 inhibitor9421
 GLP-1 agonist24991
 MET5242
 SGLT-2 inhibitor353
 SU4242
 TZDs7357
b) LVEDD 8 trails
 Control7542
 DPP-4 inhibitor2126
 GLP-1 agonist4399
 MET130
 SGLT-2 inhibitor121
 TZDs142
c) LVESD 6 trails
 Control6476
 DPP-4 inhibitor155
 GLP-1 agonist3369
 SGLT-2 inhibitor121
 TZDs142
d) LVEDV 17 trails
 Control15915
 DPP-4 inhibitor2163
 GLP-1 agonist11621
 MET2157
 SGLT-2 inhibitor117
 SU160
 TZDs297
e) LVESV 15 trails
 Control14858
 DPP-4 inhibitor192
 GLP-1 agonist11621
 MET3173
 TZDs252
f) LVMI 15 trails
 Control11416
 DPP-4 inhibitor5162
 GLP-1 agonist592
 MET2149
 SU3249
 TZDs4243
g) E/e′ 11 trails
 Control9430
 DPP-4 inhibitor372
 GLP-1 agonist6226
 MET1118
 SGLT-2 inhibitor121
 SU122
 TZDs142
h) e′ 5 trails
 Control5341
 DPP-4 inhibitor240
 GLP-1 agonist1122
 MET1118
 TZDs142
i) E/A 14 trails
 Control10378
 DPP-4 inhibitor482
 GLP-1 agonist8200
 MET4217
 SGLT-2 inhibitor121
 TZDs281
  1. e′ early diastolic velocity, E/e′ mitral inflow E velocity to tissue Doppler e′ ratio, E/A early diastolic to late diastolic velocities ratio, DPP-4 dipeptidyl peptidase-4; GLP-1 glucagon-like peptide-1, MET metformin, SGLT-2 sodium glucose cotransporter type 2, SU sulfonylurea, TZDs thiazolidinediones